Apr
16
Targeted Genetics Reports On Recombinant DNA Advisory Committee (RAC) Review Of Its Phase 1/2 Trial Of TgAAC94 For Rheumatoid Arthritis
April 16, 2008 | Leave a Comment
Targeted Genetics Corporation (Nasdaq: TGEN) gossip with the side of the city audible range conduct by the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC), which review the reflective adverse rate reported by Targeted Genetics about the loss of a forgiving participating surrounded by the Company’s Phase I/II torment of tgAAC94 [...]
